Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. (Q53269960)
Jump to navigation
Jump to search
scientific article published on 4 February 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. |
scientific article published on 4 February 2011 |
Statements
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. (English)
1 reference
1 reference
Luca Bologna
1 reference
Elisa Gotti
1 reference
Massimiliano Manganini
1 reference
Alessandro Rambaldi
1 reference
Tamara Intermesoli
1 reference
4 February 2011
1 reference
186
1 reference
3762-3769
1 reference
6
1 reference
Identifiers
1 reference